AMBRX BIOPHARMA INC-ADR
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About AMAM
Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). It uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
Find out what a historical investment in AMBRX BIOPHARMA INC-ADR would be worth today using our AMAM stock calculator.
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountAMAM FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in AMAM
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in AMAM
on Stake
Buy AMAM from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of AMAM from only US$10 with fractional shares
